Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines

Bilal Piperdi, Yi He Ling, Roman Perez-Soler

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines'. Together they form a unique fingerprint.

Medicine & Life Sciences